Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
暂无分享,去创建一个
Christian Jacques | Nizar Bahlis | Michele Cavo | Kenneth Anderson | Daniel Binder | Heinz Ludwig | Philippe Moreau | Je-Jung Lee | K. Anderson | M. Dimopoulos | J. Cavenagh | A. Dispenzieri | A. Belch | A. Oriol | P. Moreau | H. Avet-Loiseau | Je-Jung Lee | H. Ludwig | M. Delforge | T. Facon | J. de la Rubia | M. Attal | L. Qiu | D. White | J. Fermand | M. Cavo | Angela Dispenzieri | Christine I. Chen | M. Tiab | C. Hulin | K. Weisel | Thierry Facon | Albert Oriol | Javier de la Rubia | Andrew R Belch | Christine Chen | L. Benboubker | J. Catalano | A. Pinto | N. Bahlis | A. Banos | C. Geraldes | D. Binder | R. Knight | Guang Chen | Jason Van Oostendorp | C. Jacques | A. Ervin‐Haynes | Jamie Cavenagh | Katja Weisel | Meletios A Dimopoulos | Hervé Avet-Loiseau | Michel Attal | Robert Knight | Cyrille Hulin | John Catalano | Lugui Qiu | Lotfi Benboubker | Antonello Pinto | Anne Banos | Mourad Tiab | Michel Delforge | Catarina Geraldes | Darrell J White | Jean-Paul Fermand | Guang Chen | Jason Van Oostendorp | Annette Ervin-Haynes | K. Anderson
[1] M. Beksac,et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.
[2] B. Barlogie,et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. , 2014, The Lancet. Oncology.
[3] G. Morgan,et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. , 2012, Blood.
[4] A. Palumbo,et al. Multiple myeloma. , 2011, The New England journal of medicine.
[5] 高橋 聡,et al. Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .
[6] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[7] R. Fonseca,et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.
[8] M. Dimopoulos,et al. International Myeloma Working Group recommendations for global myeloma care , 2014, Leukemia.
[9] G. Morgan,et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. , 2003, The hematology journal : the official journal of the European Haematology Association.
[10] J. Miguel,et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. , 2010, The Lancet. Oncology.
[11] P. Fayers,et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. , 2011, Blood.
[12] S. Mandrekar,et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis , 2011, Leukemia.
[13] D L DeMets,et al. Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.
[14] B. Pégourié,et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[15] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[16] M. Dimopoulos,et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma , 2009, Leukemia.
[17] K. Owzar,et al. Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[18] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[19] P. Sonneveld,et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Pégourié,et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Vincenzo Callea,et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial , 2006, The Lancet.
[22] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[23] M. Gordon. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .
[24] B. Pégourié,et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.
[25] S. Pocock. Group sequential methods in the design and analysis of clinical trials , 1977 .
[26] M. Boccadoro,et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] P. Fayers,et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. , 2010, Blood.
[28] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[29] D. Esseltine,et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Hájek,et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. , 2007, European journal of cancer.
[31] M. Dimopoulos,et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). , 2013, Blood.
[32] M. Beksac,et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group , 2011, European journal of haematology.
[33] M. Dimopoulos,et al. PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study , 2013 .
[34] M. Beksac,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[35] P. Sonneveld,et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.
[36] M. Boccadoro,et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. , 2008, Blood.
[37] M. Dreyling,et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.